NO20030233L - Fremgangsmåte for å finne forbindelser som er egnet for behandling og/ellerprofylakse av fedme - Google Patents

Fremgangsmåte for å finne forbindelser som er egnet for behandling og/ellerprofylakse av fedme

Info

Publication number
NO20030233L
NO20030233L NO20030233A NO20030233A NO20030233L NO 20030233 L NO20030233 L NO 20030233L NO 20030233 A NO20030233 A NO 20030233A NO 20030233 A NO20030233 A NO 20030233A NO 20030233 L NO20030233 L NO 20030233L
Authority
NO
Norway
Prior art keywords
prophylaxis
obesity
treatment
compounds suitable
finding compounds
Prior art date
Application number
NO20030233A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030233D0 (no
Inventor
Johannes Hebebrand
Jochen Antel
Ulf Preuschoff
Samuel David
Holger Sann
Michael Weske
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of NO20030233D0 publication Critical patent/NO20030233D0/no
Publication of NO20030233L publication Critical patent/NO20030233L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20030233A 2000-07-20 2003-01-17 Fremgangsmåte for å finne forbindelser som er egnet for behandling og/ellerprofylakse av fedme NO20030233L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10035227A DE10035227A1 (de) 2000-07-20 2000-07-20 Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
PCT/EP2001/008051 WO2002007821A1 (de) 2000-07-20 2001-07-12 Verfahren zum auffinden von verbindungen, welche zur behandlung und/oder prophylaxe von obesitas geeignet sind

Publications (2)

Publication Number Publication Date
NO20030233D0 NO20030233D0 (no) 2003-01-17
NO20030233L true NO20030233L (no) 2003-03-19

Family

ID=7649538

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030233A NO20030233L (no) 2000-07-20 2003-01-17 Fremgangsmåte for å finne forbindelser som er egnet for behandling og/ellerprofylakse av fedme

Country Status (26)

Country Link
EP (1) EP1307262B1 (cs)
JP (1) JP2004504053A (cs)
KR (1) KR100818827B1 (cs)
CN (1) CN1443085B (cs)
AR (1) AR028730A1 (cs)
AT (1) ATE278441T1 (cs)
AU (2) AU2001277534B9 (cs)
BR (1) BR0112547A (cs)
CA (1) CA2416647A1 (cs)
CZ (1) CZ2003156A3 (cs)
DE (2) DE10035227A1 (cs)
DZ (1) DZ3393A1 (cs)
ES (1) ES2230346T3 (cs)
HU (1) HUP0302309A3 (cs)
IL (2) IL153971A0 (cs)
MX (1) MXPA02012907A (cs)
NO (1) NO20030233L (cs)
NZ (1) NZ523960A (cs)
PL (1) PL201165B1 (cs)
PT (1) PT1307262E (cs)
RU (1) RU2268721C2 (cs)
SK (1) SK287607B6 (cs)
TR (1) TR200402670T4 (cs)
TW (1) TWI274157B (cs)
UA (1) UA74588C2 (cs)
WO (1) WO2002007821A1 (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997370B (zh) 2004-05-19 2011-06-01 索尔瓦药物有限公司 N-氨磺酰-n＇-芳基哌嗪类化合物在制备用于预防或治疗肥胖和相关疾病的药物中的用途
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
BRPI0610864A2 (pt) 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
AR057570A1 (es) 2005-11-14 2007-12-05 Solvay Pharm Gmbh Derivados de n-sulfamoil-n'-benzopiranopiperidinas espirocondensadas, composiciones farmaceuticas que los comprenden, un procedimiento para su preparacion y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por las isoenzimas anhidrasas carbonicas subtipos ii y/o
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
JP2009537635A (ja) 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
AU2008209320B2 (en) 2007-01-25 2013-05-30 NAIA Metabolic, Inc. Insulin sensitisers and methods of treatment
PE20110060A1 (es) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
SG10201705388XA (en) * 2012-05-24 2017-07-28 Verva Pharmaceuticals Ltd A Method Of Improving Liver Function
CN106770611B (zh) * 2016-12-22 2019-01-29 广西师范大学 一种用于细胞原位检测小分子化合物进入线粒体的方法
RU2771430C1 (ru) * 2021-09-21 2022-05-04 Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) Способ количественного определения антиконвульсантов в плазме крови больных эпилепсией

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552897A (en) * 1983-02-01 1985-11-12 American Cyanamid Company Salts of 1-(aminodihalophenyl)-2-aminoethanols and antilipogenic compositions prepared therefrom
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
ZA932660B (en) * 1992-04-17 1993-10-26 Sankyo Co Derivatives of adipogenesis inhibitory factor, their preparation and their use
ES2095086T3 (es) * 1992-10-29 1997-02-01 Genentech Inc Metodo para el tratamiento y la prevencion de la obesidad.
AU693478B2 (en) * 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
SK284305B6 (sk) * 1996-06-28 2005-01-03 Ortho-Mcneil Pharmaceutical, Inc. Liečivo na liečbu obezity
US5727570A (en) * 1996-11-14 1998-03-17 Clemens; Anton H. Method of treating hyperlipidemia in humans
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor

Also Published As

Publication number Publication date
KR100818827B1 (ko) 2008-04-01
ES2230346T3 (es) 2005-05-01
EP1307262B1 (de) 2004-10-06
AU7753401A (en) 2002-02-05
KR20030022284A (ko) 2003-03-15
RU2268721C2 (ru) 2006-01-27
WO2002007821A1 (de) 2002-01-31
PT1307262E (pt) 2004-12-31
SK287607B6 (sk) 2011-03-04
TWI274157B (en) 2007-02-21
AU2001277534B9 (en) 2006-02-23
AU2001277534B2 (en) 2005-09-29
ATE278441T1 (de) 2004-10-15
NO20030233D0 (no) 2003-01-17
IL153971A (en) 2009-07-20
DE50104023D1 (de) 2004-11-11
HK1057499A1 (zh) 2004-04-08
NZ523960A (en) 2004-12-24
AR028730A1 (es) 2003-05-21
MXPA02012907A (es) 2003-09-22
IL153971A0 (en) 2003-07-31
JP2004504053A (ja) 2004-02-12
TR200402670T4 (tr) 2004-11-22
CA2416647A1 (en) 2003-01-20
HUP0302309A3 (en) 2005-06-28
PL363518A1 (en) 2004-11-29
BR0112547A (pt) 2003-07-01
CN1443085B (zh) 2010-04-28
CN1443085A (zh) 2003-09-17
UA74588C2 (en) 2006-01-16
HUP0302309A2 (hu) 2003-11-28
EP1307262A1 (de) 2003-05-07
DZ3393A1 (fr) 2002-01-31
PL201165B1 (pl) 2009-03-31
DE10035227A1 (de) 2002-01-31
CZ2003156A3 (cs) 2003-06-18
SK612003A3 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
NO20030233D0 (no) Fremgangsmåte for å finne forbindelser som er egnet for behandling og/ellerprofylakse av fedme
NO20054369D0 (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
NO20013380L (no) 2-aminobenzoksazinonderivater for behandling av fedme
NO20013381D0 (no) 2-oksybenzoksazinonderivater for behandling av fedme
NO20041216L (no) Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvekt
NO20020770L (no) Anvendelse av monoaminoksidaseinhibitorer for fremstilling av legemidler egnet for behandling av obesitas
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
SI1231920T1 (sl) Uporaba epinastina za zdravljenje alergijskega renitisa/konjuktivitisa
NO20044195L (no) Biofosfoninsyrer for behandling og prevensjon av osteoprose
NO20035610L (no) Fremgangsmate for behandling av vaeskeformig hydrokarbon
NO20021526L (no) Anordning for kloakkbehandling
NO20052476D0 (no) 2-alkyl-(2-amino-3-aryl-propionyl)-piperazinderivater og beslektede forbindelser som melanokortinreseptorligander for behandlingen av obesitet.
GB2418025B (en) Device for the prevention or treatment of ulcers
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
NO20052009D0 (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
AU2003263760A1 (en) Methods for the treatment or prevention of obesity
DK1455794T3 (da) CIC-2 kanalåbner til behandling af mave- eller tarmsår
AU2001277534A1 (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity
AU2002364171A1 (en) Materials and methods for the treatment or prevention of obesity
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
NO20026219L (no) Forbindelser for behandling av svekket fundisk relaksasjon
DK1412343T3 (da) Forbindelser, som er stærke inhibitorer af Na+/Ca2+udbytningsmekanismen og er nyttige til behandling af arytmier
SI1562577T1 (sl) Acetyl-L-karnitin za preprečevanje in/ali zdravljenje perifernih nevropatij, induciranih s talidomidom
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2001239301A1 (en) Use of ectoin or ectoin derivatives for the prophylaxis and/or treatment of uv-induced immunosuppression